A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus
Latest Information Update: 06 Feb 2024
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Reata Pharmaceuticals
- 26 Oct 2023 Planned End Date changed from 1 Oct 2013 to 31 Oct 2012.
- 26 Oct 2023 Planned initiation date changed from 1 Sep 2012 to 30 Sep 2012.
- 22 Oct 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.